Market Overview

ELIQUIS Receives Approval In Japan for Prevention of Stroke, Systemic Embolism In Patients with Nonvalvular Atrial Fibrillation

Share:
Related BMY
Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls
Bristol-Myers Squibb Posts Upbeat Q2 Results, Lifts Profit Forecast
Seattle Genetics (SGEN) Loss Widens in Q2, Ups 2015 View - Analyst Blog (Zacks)

Bristol-Myers Squibb (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced
today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has
approved ELIQUIS® (apixaban) for the prevention of
ischemic stroke and systemic embolism in patients with nonvalvular
atrial fibrillation (NVAF). ELIQUIS is a novel anticoagulant that has
demonstrated risk reductions versus warfarin in three important outcomes
of stroke, major bleeding and all-cause death. ELIQUIS is an oral direct
Factor Xa inhibitor, part of a novel therapeutic class. This is the
third approval for ELIQUIS for the prevention of stroke and systemic
embolism in patients with nonvalvular atrial fibrillation, following
approvals in the European Union and Canada.

“Today's approval of ELIQUIS is

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (BMY + PFE)

Get Benzinga's Newsletters